CoChat
Sign Up
Cited by 216

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection

Biffi, Alessandra, Bartolomae, Cynthia C., Cesana, Daniela, Cartier, Natalie, Aubourg, Patrik, Ranzani, Marco, Cesani, Martina, Benedicenti, Fabrizio, Plati, Tiziana, Rubagotti, Enrico, Merella, Stefania, Capotondo, Alessia, Sgualdino, Jacopo, Zanetti, Gianluigi, von Kalle, Christof, Schmidt, Manfred, Naldini, Luigi, Montini, Eugenio·2011·Blood
DOI 10.1182/blood-2010-09-306761
Open this paper in CoChat — free account

Abstract

A recent clinical trial for adrenoleukodystrophy (ALD) showed the efficacy and safety of lentiviral vector (LV) gene transfer in hematopoietic stem progenitor cells. However, several common insertion sites (CIS) were found in patients' cells, suggesting that LV integrations conferred a selective advantage. We performed high-throughput LV integration site analysis on human hematopoietic stem progenitor cells engrafted in immunodeficient mice and found the same CISs reported in patients with ALD. Strikingly, most CISs in our experimental model and in patients with ALD cluster in megabase-wide chromosomal regions of high LV integration density. Conversely, cancer-triggering integrations at CISs found in tumor cells from γretroviral vector–based clinical trials and oncogene-tagging screenings in mice always target a single gene and are contained in narrow genomic intervals. These findings imply that LV CISs are produced by an integration bias toward specific genomic regions rather than by oncogenic selection.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2010-09-306761

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 45

  1. Aiuti, 2002, Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning., Science, 296, 2410, 10.1126/science.1070104 · DOI · Paper page
  2. Hacein-Bey-Abina, 2002, Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy., N Engl J Med, 346, 1185, 10.1056/NEJMoa012616 · DOI
  3. Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1., Science, 302, 415, 10.1126/science.1088547 · DOI · Paper page
  4. Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1., Nat Med, 4, 401, 10.1038/nm1393 · DOI · Paper page
  5. Deichmann, 2007, Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy., J Clin Invest, 117, 2225, 10.1172/JCI31659 · DOI
  6. Schwarzwaelder, 2007, Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo., J Clin Invest, 117, 2241, 10.1172/JCI31661 · DOI
  7. Modlich, 2006, Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity., Blood, 108, 2545, 10.1182/blood-2005-08-024976 · DOI · Paper page
  8. Modlich, 2009, Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors., Mol Ther, 17, 1919, 10.1038/mt.2009.179 · DOI · Paper page
  9. Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration., Nat Biotechnol, 24, 687, 10.1038/nbt1216 · DOI
  10. Naldini, 2009, Medicine. A comeback for gene therapy., Science, 326, 805, 10.1126/science.1181937 · DOI
  11. Kool, 2009, High-throughput insertional mutagenesis screens in mice to identify oncogenic networks., Nat Rev Cancer, 9, 389, 10.1038/nrc2647 · DOI
  12. Akagi, 2004, RTCGD: retroviral tagged cancer gene database., Nucleic Acids Res, 32, D523, 10.1093/nar/gkh013 · DOI
  13. Baum, 2007, Insertional mutagenesis in gene therapy and stem cell biology., Curr Opin Hematol, 14, 337, 10.1097/MOH.0b013e3281900f01 · DOI
  14. Capotondo, 2007, Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy., Hum Gene Ther, 18, 821, 10.1089/hum.2007.048 · DOI
  15. Follenzi, 2002, HIV-based vectors. Preparation and use., Methods Mol Med, 69, 259
  16. Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency., N Engl J Med, 360, 447, 10.1056/NEJMoa0805817 · DOI
  17. Folks, 1985, Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus., Proc Natl Acad Sci U S A, 82, 4539, 10.1073/pnas.82.13.4539 · DOI
  18. Biffi, 2006, Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice., J Clin Invest, 116, 3070, 10.1172/JCI28873 · DOI
  19. Abel, 2007, Real-time definition of non-randomness in the distribution of genomic events., PLoS ONE, 2, e570, 10.1371/journal.pone.0000570 · DOI
  20. Kool, 2010, Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes., Cancer Res, 70, 520, 10.1158/0008-5472.CAN-09-2736 · DOI
  21. Uren, 2008, Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks., Cell, 133, 727, 10.1016/j.cell.2008.03.021 · DOI
  22. Bokhoven, 2009, Insertional gene activation by lentiviral and gammaretroviral vectors., J Virol, 83, 283, 10.1128/JVI.01865-08 · DOI · Paper page
  23. Wu, 2006, Redefining the common insertion site., J Virol, 344, 292, 10.1016/j.virol.2005.08.047 · DOI
  24. Wang, 2010, Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial., Blood, 115, 4356, 10.1182/blood-2009-12-257352 · DOI
  25. Dave, 2009, Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy., PLoS Genet, 5, e1000491, 10.1371/journal.pgen.1000491 · DOI
  26. Lewinski, 2005, Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription., J Virol, 79, 6610, 10.1128/JVI.79.11.6610-6619.2005 · DOI
  27. Carteau, 1998, Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target., J Virol, 72, 4005, 10.1128/JVI.72.5.4005-4014.1998 · DOI
  28. Li, 2000, Retroviral cDNA integration: stimulation by HMG I family proteins., J Virol, 74, 10965, 10.1128/JVI.74.23.10965-10974.2000 · DOI
  29. Schroder, 2002, HIV-1 integration in the human genome favors active genes and local hotspots., Cell, 110, 521, 10.1016/S0092-8674(02)00864-4 · DOI · Paper page
  30. Ciuffi, 2006, Retroviral DNA integration: HIV and the role of LEDGF/p75., Trends Genet, 22, 388, 10.1016/j.tig.2006.05.006 · DOI
  31. Lewinski, 2006, Retroviral DNA integration: viral and cellular determinants of target-site selection., PLoS Pathog, 2, e60, 10.1371/journal.ppat.0020060 · DOI · Paper page
  32. Wang, 2007, HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications., Genome Res, 17, 1186, 10.1101/gr.6286907 · DOI · Paper page
  33. Brady, 2009, HIV integration site distributions in resting and activated CD4+ T cells infected in culture., AIDS, 23, 1461, 10.1097/QAD.0b013e32832caf28 · DOI
  34. Bushman, 2009, Host cell factors in HIV replication: meta-analysis of genome-wide studies., PLoS Pathog, 5, e1000437, 10.1371/journal.ppat.1000437 · DOI
  35. Wang, 2009, Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells., Mol Ther, 17, 844, 10.1038/mt.2009.16 · DOI
  36. Vatakis, 2009, Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells., J Virol, 83, 6222, 10.1128/JVI.00356-09 · DOI
  37. Felice, 2009, Transcription factor binding sites are genetic determinants of retroviral integration in the human genome., PLoS ONE, 4, e4571, 10.1371/journal.pone.0004571 · DOI
  38. Albanese, 2008, HIV-1 pre-integration complexes selectively target decondensed chromatin in the nuclear periphery., PLoS ONE, 3, e2413, 10.1371/journal.pone.0002413 · DOI
  39. MacNeil, 2006, Genomic sites of human immunodeficiency virus type 2 (HIV-2) integration: similarities to HIV-1 in vitro and possible differences in vivo., J Virol, 80, 7316, 10.1128/JVI.00604-06 · DOI
  40. Iglewicz, 1993, How to Detect and Handle Outliers
  41. Barnett, 1994, Outliers in Statistical Data
  42. Biasco, 2011, Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell., EMBO Mol Medicine, 3, 89, 10.1002/emmm.201000108 · DOI
  43. Boztug, 2010, Stem-cell gene therapy for the Wiskott-Aldrich syndrome., N Engl J Med, 363, 1918, 10.1056/NEJMoa1003548 · DOI · Paper page
  44. de Ridder, 2006, Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens., PLoS Comput Biol, 2, e166, 10.1371/journal.pcbi.0020166 · DOI
  45. Rad, 2010, PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice., Science, 330, 1104, 10.1126/science.1193004 · DOI

Cited by

See all 216

Metadata

Authors
Biffi, A., Bartolomae, C. C., Cesana, D., Cartier, N., Aubourg, P., Ranzani, M., Cesani, M., Benedicenti, F., Plati, T., Rubagotti, E., Merella, S., Capotondo, A., Sgualdino, J., Zanetti, G., von Kalle, C., Schmidt, M., Naldini, L., & Montini, E.
Affiliations
  • San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan, Italy;
  • National Center for Tumor Diseases, Heidelberg, Germany;
  • Inserm UMR745, University Paris-Descartes, Paris, France; and
  • Distributed Computing Group, Center for Advanced Studies, Research, and Development in Sardinia (CRS4), Pula, Italy
Venue
Blood
Publisher
American Society of Hematology
Published
2011-05-19
Volume
117
Issue
20
Pages
5332-5339
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2010-09-306761
Cited by
216
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review